YOLFTbeta
NeoCore Technology Co., Ltd.

NeoCore Technology Co., Ltd.

4131 · TWO · Healthcare / Biotechnology

30.55TWD-0.40 (-1.29%)

Price History

Full chart

Market Stats

Previous Close30.95
Open30.85
Day Range30.15 – 30.85
52-Week Range29.20 – 42.45
Volume14.02K
Market Cap1.23B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.84
Dividend Yield0.00%
Beta-0.28
50-Day Avg31.99
200-Day Avg35.45

About

NeoCore Technology Co., Ltd. designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices. The company's products include food safety testing kits, including DR. Meat Kit, DR. Food-Ent kit, rapid test kit, and ELISA kit; infectious disease testing, such as DR. HPV Genotyping IVD Kit, DR. MTBC Screen IVD Kit, and DR. Microorganism IVD Kit (Non-sterile); and biochip instruments and equipment, including DR. AiM Reader, DR.Mini Oven, and DR.Fluidic Station. In addition, the company engages in the wholesale and retail of contact lenses. The company was formerly known as DR. Chip Biotechnology Incorporation and changed its name to NeoCore Technology Co., Ltd. in July 2023. NeoCore Technology Co., Ltd. was founded in 1987 and is headquartered in Tainan City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Wen-Sheng Ji
  • Employees0
  • HeadquartersNo. 395, Linsen Road, Tainan City, Taiwan, 701, Taiwan
  • Websitehttps://www.neocore.com.tw

Leadership

  • Mr. Wen-Sheng JiGeneral Manager
  • Jack LeeFinancial Legal Manager
  • Yen-Chueh YangAdministration Department Manager

Financials

Income Statement

Currency: TWD2021-12-312022-12-312023-12-312024-12-31
Total Revenue88.93M88.97M64.73M61.55M
Growth (%)-+0.05%-27.24%-4.92%
Cost of Revenue69.53M77.18M73.81M58.25M
Gross Profit19.40M11.78M-9.09M3.29M
Gross Margin21.82%13.25%-14.04%5.35%
Operating Expense47.69M52.05M75.83M79.13M
Operating Income-28.29M-40.26M-84.91M-75.83M
Operating Margin-31.81%-45.26%-131.18%-123.22%
EBITDA--29.49M-72.11M-46.34M
EBITDA Margin--33.14%-111.41%-75.29%
Net Income-17.20M-28.21M-64.64M-48.14M
Net Income Margin-19.34%-31.71%-99.87%-78.21%
R&D5.63M6.89M24.95M15.59M
R&D as % of Total Revenue6.34%7.75%38.54%25.32%
Interest Expense1.83M2.00M2.37M2.10M
Interest Expense % of Total Revenue2.06%2.25%3.65%3.41%

Balance Sheet

Currency: TWD2021-12-312022-12-312023-12-312024-12-31
Total Assets281.96M266.79M548.75M340.76M
Total Liabilities164.60M185.81M197.47M35.67M
Total Equity112.05M75.93M347.68M305.09M
Cash10.37M40.26M293.29M207.99M
Net Debt49.63M39.74M--

Cash Flow

Currency: TWD2007-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow--17.15M-2.69M-63.88M-57.15M
Capital Expenditure00737.00K11.53M12.50M
Free Cash Flow--17.15M-3.43M-75.42M-69.66M
FCF to OCF-100.00%127.41%118.05%121.88%

Earnings

Report DateAug 28, 2008Apr 30, 2009
EPS Estimate0.421.44
EPS Actual0.03-0.51
Surprise-92.86%-135.42%
TimingAfter-hoursPre-market

Key Statistics & Ratios

Market Cap1.23B
Enterprise Value1.40B
Trailing P/E0.00
Forward P/E0.00
Price / Sales4.42
Price / Book4.49
EPS-0.84
Book Value7.19
Revenue (TTM)277.54M
Gross Profit (TTM)110.17M
EBITDA-7.22M
Profit Margin-11.93%
Operating Margin4.65%
Return on Equity-10.63%
Return on Assets-3.47%
Shares Outstanding39.81M
Shares Float11.97M
Beta-0.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 29, 2021393.4404:1000